Though opioid prescriptions appear to be on the decline, Vicodin and Norco remain popular, especially in the South. In more than half of states, Synthroid — a drug to treat hypothyroidism — came in at No. 1.
Health care tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
Purdue Pharma, whose signature product helped fuel the opioid epidemic, now wants to help treat it — or at least salvage its own reputation.
The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.
Few bonds are as tight as those between sisters. But when one has paranoid schizophrenia, the relationship grows complicated.
Premature death, a dearth of treatments, mistreatment in emergency rooms and a woeful lack of funding are just a few of the problems confronting people with sickle cell disease.
Behavioral care was at least four times more likely to be out-of-network than medical or surgical care, an analysis by Milliman shows.
People with the genetic blood disorder that mainly afflicts African-Americans can live into their 60s with competent care. So why is life expectancy slipping down to around age 40?
Not only are health prices hidden, industry players are contractually obligated to keep them secret. That’s why answering a simple question — how much does it cost to have a baby in Mountain View, Calif.? — became a journalistic quest.
Gobbling up doctors’ independent practices is lucrative for hospital systems — but not necessarily a good deal for the physicians or consumers, critics say. Northern California is a case in point.